The association of level of reduction of Wilms’ tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients
| Autor: | Hirohito Sone, Jun Takizawa, Masayoshi Masuko, Masato Moriyama, Kyoko Fuse, Toshio Yano, Yasuhiko Shibasaki, Tatsuo Furukawa, Miwako Narita, Takashi Kuroha, Hironori Kobayashi, Koyama S, Takashi Abe, Noriatsu Isahai, Yoshinobu Seki, Syukuko Miyakoshi, Takashi Ushiki, Tomoyuki Tanaka, Takashi Kozakai |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Disease-Free Survival Bone Marrow Risk Factors Internal medicine medicine Humans RNA Messenger RNA Neoplasm WT1 Proteins Gene Reduction (orthopedic surgery) Aged Messenger RNA business.industry Myeloid leukemia Wilms' tumor Adult Acute Myeloid Leukemia Induction Chemotherapy Hematology Middle Aged medicine.disease Minimal residual disease Consolidation Chemotherapy Survival Rate Leukemia Myeloid Acute medicine.anatomical_structure Immunology Bone marrow business |
| Zdroj: | Leukemia Research. 39:667-671 |
| ISSN: | 0145-2126 |
| Popis: | We focused on the level of reduction of Wilms' tumor gene 1 (WT1) mRNA in bone marrow as minimal residual disease during chemotherapies in adult acute myeloid leukemia (AML) patients. Forty-eight patients were enrolled in this study. Log levels of reduction of WT1 mRNA transcript after induction therapy compared with those at diagnosis were associated with disease-free survival (DFS) (P=0.0066) and overall survival (OS) (P=0.0074) in patients who achieved complete remission. Also log levels of reduction of WT1 mRNA transcript after final consolidation therapy compared with those at diagnosis were associated with DFS (P=0.015) and OS (P=0.012). By multivariate analysis, log levels of reduction of WT1 mRNA transcript after induction therapy and after final consolidation therapy compared with those at diagnosis were extracted as risk factors for outcome. Our results suggest that early and deep reduction of tumor burden may be important for the outcome of AML patients. In addition, it may be useful for the decision to proceed with allogeneic SCT as post-remission therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect